指南与共识其他结缔组织病系统性红斑狼疮

EULAR成人抗磷脂综合征管理建议

EULAR recommendations for the management of antiphospholipid syndrome in adults.
指南 / 共识 · Ann Rheum Dis · 2019-05-15

该建议基于系统文献综述与专家意见制定,针对成人抗磷脂综合征(APS)提出管理原则与推荐。核心包括高危aPL画像的血栓与产科风险分层、低剂量阿司匹林用于无症状携带者等高危人群、VKA为血栓性APS主要治疗且利伐沙班不用于三重aPL阳性者、妊娠期低剂量阿司匹林联合预防剂量肝素。高质量证据有限。

要点

  • 高危aPL画像与血栓及产科APS风险增加相关,需进行风险因素筛查与管理。
  • 无症状高危aPL携带者、无血栓/产科APS的SLE患者及仅产科APS史非妊娠女性推荐低剂量阿司匹林。
  • 三重aPL阳性APS患者不应使用利伐沙班。

核心结论

  • 基于系统文献综述与专家意见形成成人APS管理推荐,高质量证据有限,需更多研究。

研究设计与样本

  • 基于系统文献综述证据与专家意见制定总体原则和推荐并进行投票。

主要发现

  • 高危aPL画像与血栓性和产科APS风险增加相关。
  • 风险修正包括筛查和管理心血管及静脉血栓风险因素、患者教育关于治疗依从性及生活方式咨询。

关键数值与推荐

  • 无症状aPL携带者、无既往血栓或产科APS的SLE患者、仅有产科APS史的非妊娠女性,均具高危aPL画像者推荐低剂量阿司匹林。
  • APS首次无诱因静脉血栓者推荐长期维生素K拮抗剂(VKA)治疗,目标INR 2-3。
  • APS首次动脉血栓者推荐VKA治疗INR 2-3或INR 3-4,需考虑个体出血/血栓风险。
  • 三重aPL阳性APS患者不应使用利伐沙班。
  • 既往产科APS孕妇推荐妊娠期低剂量阿司匹林联合预防剂量肝素。

临床怎么用

  • 对高危aPL画像者进行风险因素筛查与管理,并开展治疗依从性教育和生活方式咨询。
  • 血栓性APS以VKA为主要抗凝选择,根据血栓类型和个体风险确定INR目标。
  • 妊娠期产科APS采用低剂量阿司匹林联合预防剂量肝素;复发妊娠并发症可考虑增加肝素至治疗剂量、加用羟氯喹或早孕期加用低剂量泼尼松龙。

局限性

  • 高质量证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening for and management of cardiovascular and venous thrombosis risk factors, patient education about treatment adherence, and lifestyle counselling. Low-dose aspirin (LDA) is recommended for asymptomatic aPL carriers, patients with systemic lupus erythematosus without prior thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only, all with high-risk aPL profiles. Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3. In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk. Rivaroxaban should not be used in patients with APS with triple aPL positivity. For patients with recurrent arterial or venous thrombosis despite adequate treatment, addition of LDA, increase of INR target to 3-4 or switch to low molecular weight heparin may be considered. In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended. In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered. These recommendations aim to guide treatment in adults with APS. High-quality evidence is limited, indicating a need for more research.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019. PMID: 31092409. doi:10.1136/annrheumdis-2019-215213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。